CN107249611A - 活化的双歧杆菌及其应用方法 - Google Patents
活化的双歧杆菌及其应用方法 Download PDFInfo
- Publication number
- CN107249611A CN107249611A CN201580071135.XA CN201580071135A CN107249611A CN 107249611 A CN107249611 A CN 107249611A CN 201580071135 A CN201580071135 A CN 201580071135A CN 107249611 A CN107249611 A CN 107249611A
- Authority
- CN
- China
- Prior art keywords
- composition
- bifidobacterium
- lactose
- oligosaccharides
- blon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000186000 Bifidobacterium Species 0.000 title claims abstract description 111
- 238000000034 method Methods 0.000 title claims abstract description 103
- 230000004913 activation Effects 0.000 title claims abstract description 38
- 230000008569 process Effects 0.000 title description 3
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 245
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 242
- 239000000203 mixture Substances 0.000 claims abstract description 188
- 239000002131 composite material Substances 0.000 claims abstract description 78
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 57
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 57
- 108090000623 proteins and genes Proteins 0.000 claims description 57
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 56
- 239000008101 lactose Substances 0.000 claims description 56
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 44
- 244000005700 microbiome Species 0.000 claims description 43
- 241000894006 Bacteria Species 0.000 claims description 34
- 241001608472 Bifidobacterium longum Species 0.000 claims description 33
- 210000004080 milk Anatomy 0.000 claims description 31
- 239000008267 milk Substances 0.000 claims description 31
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 30
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 30
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 30
- 235000020256 human milk Nutrition 0.000 claims description 30
- 210000004251 human milk Anatomy 0.000 claims description 30
- 235000013336 milk Nutrition 0.000 claims description 30
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 claims description 28
- 210000003022 colostrum Anatomy 0.000 claims description 27
- 235000021277 colostrum Nutrition 0.000 claims description 27
- 229940060155 neuac Drugs 0.000 claims description 23
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 claims description 23
- 241000124008 Mammalia Species 0.000 claims description 22
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 22
- 235000020247 cow milk Nutrition 0.000 claims description 19
- FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 17
- 239000002775 capsule Substances 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- -1 6 '-sialyl lactose Amine Chemical class 0.000 claims description 14
- 235000013350 formula milk Nutrition 0.000 claims description 14
- 235000000346 sugar Nutrition 0.000 claims description 14
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 210000000936 intestine Anatomy 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 10
- 210000002784 stomach Anatomy 0.000 claims description 10
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 9
- 208000034423 Delivery Diseases 0.000 claims description 9
- 238000000855 fermentation Methods 0.000 claims description 9
- 230000004151 fermentation Effects 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 9
- 241000195493 Cryptophyta Species 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 239000005862 Whey Substances 0.000 claims description 8
- 102000007544 Whey Proteins Human genes 0.000 claims description 8
- 108010046377 Whey Proteins Proteins 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 8
- 210000003608 fece Anatomy 0.000 claims description 8
- 229920000642 polymer Polymers 0.000 claims description 8
- 239000011435 rock Substances 0.000 claims description 8
- 241000186012 Bifidobacterium breve Species 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 7
- 150000002972 pentoses Chemical class 0.000 claims description 7
- 230000035935 pregnancy Effects 0.000 claims description 7
- 210000003296 saliva Anatomy 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- 230000003827 upregulation Effects 0.000 claims description 7
- 230000009677 vaginal delivery Effects 0.000 claims description 7
- TYALNJQZQRNQNQ-UHFFFAOYSA-N #alpha;2,6-sialyllactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OCC1C(O)C(O)C(O)C(OC2C(C(O)C(O)OC2CO)O)O1 TYALNJQZQRNQNQ-UHFFFAOYSA-N 0.000 claims description 6
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 102000012086 alpha-L-Fucosidase Human genes 0.000 claims description 6
- 108010061314 alpha-L-Fucosidase Proteins 0.000 claims description 6
- 229930000044 secondary metabolite Natural products 0.000 claims description 6
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 5
- 241001494479 Pecora Species 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 5
- 238000012544 monitoring process Methods 0.000 claims description 5
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- 238000012384 transportation and delivery Methods 0.000 claims description 5
- 235000013618 yogurt Nutrition 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
- 241000283707 Capra Species 0.000 claims description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000002550 fecal effect Effects 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 238000003306 harvesting Methods 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 229920003023 plastic Polymers 0.000 claims description 4
- 239000004033 plastic Substances 0.000 claims description 4
- 235000021391 short chain fatty acids Nutrition 0.000 claims description 4
- 150000004666 short chain fatty acids Chemical class 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229920002494 Zein Polymers 0.000 claims description 3
- 108010055615 Zein Proteins 0.000 claims description 3
- TYALNJQZQRNQNQ-JLYOMPFMSA-N alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O1 TYALNJQZQRNQNQ-JLYOMPFMSA-N 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 230000009969 flowable effect Effects 0.000 claims description 3
- 230000002068 genetic effect Effects 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 claims description 3
- IBONACLSSOLHFU-KEWYIRBNSA-N n-[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]acetamide Chemical compound CC(=O)NC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBONACLSSOLHFU-KEWYIRBNSA-N 0.000 claims description 3
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 125000005630 sialyl group Chemical group 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- 241001134772 Bifidobacterium pseudocatenulatum Species 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 241000792859 Enema Species 0.000 claims description 2
- 229920003141 Eudragit® S 100 Polymers 0.000 claims description 2
- 229920002527 Glycogen Polymers 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000001888 Peptone Substances 0.000 claims description 2
- 108010080698 Peptones Proteins 0.000 claims description 2
- 229920001800 Shellac Polymers 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 229960003237 betaine Drugs 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 229960004203 carnitine Drugs 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 claims description 2
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 239000007920 enema Substances 0.000 claims description 2
- 229940095399 enema Drugs 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 2
- 229940096919 glycogen Drugs 0.000 claims description 2
- 238000011081 inoculation Methods 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 2
- IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 claims description 2
- 235000013923 monosodium glutamate Nutrition 0.000 claims description 2
- 235000019319 peptone Nutrition 0.000 claims description 2
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 claims description 2
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 2
- 239000004208 shellac Substances 0.000 claims description 2
- 229940113147 shellac Drugs 0.000 claims description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 2
- 235000013874 shellac Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 229940073490 sodium glutamate Drugs 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 229960003080 taurine Drugs 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acetylhexosamine Chemical compound CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims 42
- 241000282836 Camelus dromedarius Species 0.000 claims 4
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 4
- 241000282898 Sus scrofa Species 0.000 claims 4
- 102000005348 Neuraminidase Human genes 0.000 claims 2
- 108010006232 Neuraminidase Proteins 0.000 claims 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 244000060011 Cocos nucifera Species 0.000 claims 1
- 235000013162 Cocos nucifera Nutrition 0.000 claims 1
- 241001151130 Eilema Species 0.000 claims 1
- 241000283073 Equus caballus Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 241000628997 Flos Species 0.000 claims 1
- 229920001503 Glucan Polymers 0.000 claims 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- 241000406668 Loxodonta cyclotis Species 0.000 claims 1
- 241001416149 Ovis ammon Species 0.000 claims 1
- 241000009328 Perro Species 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 235000020246 buffalo milk Nutrition 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000003831 deregulation Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000000047 product Substances 0.000 description 23
- 210000000481 breast Anatomy 0.000 description 19
- 150000002402 hexoses Chemical class 0.000 description 18
- 230000012010 growth Effects 0.000 description 16
- 150000004676 glycans Chemical class 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 11
- 150000001412 amines Chemical group 0.000 description 10
- 238000001035 drying Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000035611 feeding Effects 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 7
- 239000013589 supplement Substances 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 235000013365 dairy product Nutrition 0.000 description 6
- 238000005238 degreasing Methods 0.000 description 6
- 108091008053 gene clusters Proteins 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 235000020183 skimmed milk Nutrition 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 230000035606 childbirth Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 244000000010 microbial pathogen Species 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000004347 intestinal mucosa Anatomy 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 235000004252 protein component Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 210000001215 vagina Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100040837 Galactoside alpha-(1,2)-fucosyltransferase 2 Human genes 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 150000008267 fucoses Chemical class 0.000 description 3
- 108010079306 galactoside 2-alpha-L-fucosyltransferase Proteins 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 description 3
- USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000000474 nursing effect Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- ZEPAXLPHESYSJU-UHFFFAOYSA-N 2,3,4,5,6,7,8-heptahydroxyoctanal Chemical compound OCC(O)C(O)C(O)C(O)C(O)C(O)C=O ZEPAXLPHESYSJU-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- OVRNDRQMDRJTHS-BKJPEWSUSA-N N-acetyl-D-hexosamine Chemical class CC(=O)NC1C(O)O[C@H](CO)C(O)C1O OVRNDRQMDRJTHS-BKJPEWSUSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 2
- PDWGIAAFQACISG-QZBWVFMZSA-N beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->3)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)]-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)OC[C@@H]1[C@@H]([C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O1)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O PDWGIAAFQACISG-QZBWVFMZSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000001842 enterocyte Anatomy 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 101150027052 hmo gene Proteins 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940062780 lacto-n-neotetraose Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 150000002772 monosaccharides Chemical group 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- CILYIEBUXJIHCO-UHFFFAOYSA-N 102778-91-6 Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC2C(C(O)C(O)OC2CO)O)OC(CO)C1O CILYIEBUXJIHCO-UHFFFAOYSA-N 0.000 description 1
- KQMCGGGTJKNIMC-UHFFFAOYSA-N 2-hydroxy-3-propyl-2h-furan-5-one Chemical compound CCCC1=CC(=O)OC1O KQMCGGGTJKNIMC-UHFFFAOYSA-N 0.000 description 1
- DVGKRPYUFRZAQW-UHFFFAOYSA-N 3 prime Natural products CC(=O)NC1OC(CC(O)C1C(O)C(O)CO)(OC2C(O)C(CO)OC(OC3C(O)C(O)C(O)OC3CO)C2O)C(=O)O DVGKRPYUFRZAQW-UHFFFAOYSA-N 0.000 description 1
- 108010011619 6-Phytase Proteins 0.000 description 1
- 206010003402 Arthropod sting Diseases 0.000 description 1
- 241001655328 Bifidobacteriales Species 0.000 description 1
- 241000186011 Bifidobacterium catenulatum Species 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010019236 Fucosyltransferases Proteins 0.000 description 1
- 102000006471 Fucosyltransferases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 206010021746 Infantile colic Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- GKEWHGPIQCSUCC-JJGOEJEFSA-N Monofucosyllacto-N-hexaose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)C[C@@H](OO[C@@H]2[C@@H]([C@H](O[C@H]3[C@@H](C(O[C@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O2)O)[C@@H]1NC(C)=O GKEWHGPIQCSUCC-JJGOEJEFSA-N 0.000 description 1
- CILYIEBUXJIHCO-UITFWXMXSA-N N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O[C@H](CO)[C@@H]1O CILYIEBUXJIHCO-UITFWXMXSA-N 0.000 description 1
- OIZGSVFYNBZVIK-UHFFFAOYSA-N N-acetylneuraminosyl-D-lactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1O OIZGSVFYNBZVIK-UHFFFAOYSA-N 0.000 description 1
- SUHQNCLNRUAGOO-UHFFFAOYSA-N N-glycoloyl-neuraminic acid Natural products OCC(O)C(O)C(O)C(NC(=O)CO)C(O)CC(=O)C(O)=O SUHQNCLNRUAGOO-UHFFFAOYSA-N 0.000 description 1
- FDJKUWYYUZCUJX-UHFFFAOYSA-N N-glycolyl-beta-neuraminic acid Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1NC(=O)CO FDJKUWYYUZCUJX-UHFFFAOYSA-N 0.000 description 1
- 229910000503 Na-aluminosilicate Inorganic materials 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 101710199916 Phage shock protein C Proteins 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 239000004115 Sodium Silicate Substances 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102100025292 Stress-induced-phosphoprotein 1 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- KMWBBMXGHHLDKL-UHFFFAOYSA-N [AlH3].[Si] Chemical compound [AlH3].[Si] KMWBBMXGHHLDKL-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- RPSBVJXBTXEJJG-LURNZOHQSA-N alpha-N-acetylneuraminyl-(2->6)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)O1 RPSBVJXBTXEJJG-LURNZOHQSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- DLHONNLASJQAHX-UHFFFAOYSA-N aluminum;potassium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Al+3].[Si+4].[Si+4].[Si+4].[K+] DLHONNLASJQAHX-UHFFFAOYSA-N 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- AXQLFFDZXPOFPO-FSGZUBPKSA-N beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)C(O)O[C@@H]1CO AXQLFFDZXPOFPO-FSGZUBPKSA-N 0.000 description 1
- IEQCXFNWPAHHQR-YKLSGRGUSA-N beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O IEQCXFNWPAHHQR-YKLSGRGUSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 235000019347 bone phosphate Nutrition 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000279 calcium ferrocyanide Substances 0.000 description 1
- 235000012251 calcium ferrocyanide Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- SUSQQDGHFAOUBW-PVLJGHBYSA-N difucosyllacto-n-hexaose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](C)O[C@@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO[C@H]3[C@@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](C)O4)O)[C@H](O[C@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)[C@@H]2O)O)O[C@@H]1CO SUSQQDGHFAOUBW-PVLJGHBYSA-N 0.000 description 1
- BCUMESVDMXHZRL-UHFFFAOYSA-N difucosyllacto-n-hexaose i Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(C(NC(C)=O)C(OC4C(C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C4O)O)OC3CO)OC3C(C(O)C(O)C(C)O3)O)OC(CO)C2O)O)OC1CO BCUMESVDMXHZRL-UHFFFAOYSA-N 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 210000004921 distal colon Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- LUJQXGBDWAGQHS-UHFFFAOYSA-N ethenyl acetate;phthalic acid Chemical compound CC(=O)OC=C.OC(=O)C1=CC=CC=C1C(O)=O LUJQXGBDWAGQHS-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229930193965 lacto-N-fucopentaose Natural products 0.000 description 1
- 230000004576 lipid-binding Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 238000012543 microbiological analysis Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000045246 noggin Human genes 0.000 description 1
- 108700007229 noggin Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-N o-dicarboxybenzene Natural products OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 229910052652 orthoclase Inorganic materials 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 239000000429 sodium aluminium silicate Substances 0.000 description 1
- 235000012217 sodium aluminium silicate Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000000264 sodium ferrocyanide Substances 0.000 description 1
- GTSHREYGKSITGK-UHFFFAOYSA-N sodium ferrocyanide Chemical compound [Na+].[Na+].[Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] GTSHREYGKSITGK-UHFFFAOYSA-N 0.000 description 1
- 235000012247 sodium ferrocyanide Nutrition 0.000 description 1
- 235000019795 sodium metasilicate Nutrition 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 229910052911 sodium silicate Inorganic materials 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 150000003538 tetroses Chemical class 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/529—Infantis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111546347.2A CN114376234A (zh) | 2014-10-24 | 2015-10-23 | 活化的双歧杆菌及其应用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462068553P | 2014-10-24 | 2014-10-24 | |
| US62/068,553 | 2014-10-24 | ||
| US201562133243P | 2015-03-13 | 2015-03-13 | |
| US62/133,243 | 2015-03-13 | ||
| PCT/US2015/057226 WO2016065324A1 (en) | 2014-10-24 | 2015-10-23 | Activated bifidobacteria and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111546347.2A Division CN114376234A (zh) | 2014-10-24 | 2015-10-23 | 活化的双歧杆菌及其应用方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107249611A true CN107249611A (zh) | 2017-10-13 |
Family
ID=55761664
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111546347.2A Pending CN114376234A (zh) | 2014-10-24 | 2015-10-23 | 活化的双歧杆菌及其应用方法 |
| CN201580071135.XA Pending CN107249611A (zh) | 2014-10-24 | 2015-10-23 | 活化的双歧杆菌及其应用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111546347.2A Pending CN114376234A (zh) | 2014-10-24 | 2015-10-23 | 活化的双歧杆菌及其应用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10716816B2 (pt) |
| EP (1) | EP3209308B1 (pt) |
| CN (2) | CN114376234A (pt) |
| AU (2) | AU2015335601A1 (pt) |
| BR (1) | BR112017008284A8 (pt) |
| CA (1) | CA2965663C (pt) |
| DK (1) | DK3209308T3 (pt) |
| MX (1) | MX2017005260A (pt) |
| SG (2) | SG11201703298SA (pt) |
| WO (1) | WO2016065324A1 (pt) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111826324A (zh) * | 2020-08-05 | 2020-10-27 | 厦门惠盈动物科技有限公司 | 一种鼠李糖乳杆菌菌粉的制备方法 |
| CN113164532A (zh) * | 2018-05-30 | 2021-07-23 | 进化生物系统股份有限公司 | H5功能性长双歧杆菌婴儿亚种的组合物和使用方法 |
| CN113163836A (zh) * | 2018-06-01 | 2021-07-23 | 进化生物系统股份有限公司 | 促进宿主防御和刺激、扩增和/或重置t细胞库的组合物和方法 |
| CN114568520A (zh) * | 2020-11-30 | 2022-06-03 | 内蒙古伊利实业集团股份有限公司 | 包含长双歧杆菌婴儿亚种的婴幼儿配方粉及其应用 |
| CN114568516A (zh) * | 2020-11-30 | 2022-06-03 | 内蒙古伊利实业集团股份有限公司 | 包含长双歧杆菌婴儿亚种与母乳低聚糖的组合物及其应用 |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| DK3209308T3 (da) | 2014-10-24 | 2022-10-03 | Evolve Biosystems Inc | Aktiverede bifidobakterier og fremgangsmåder til anvendelse deraf |
| GB2551642B (en) | 2014-10-31 | 2020-09-23 | Pendulum Therapeutics Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| NO3065748T3 (pt) | 2014-12-23 | 2018-04-21 | ||
| SI3193901T1 (en) | 2014-12-23 | 2018-06-29 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| US20180078572A1 (en) * | 2015-03-05 | 2018-03-22 | Nestec S.A. | Compositions for use in improving stool consistency or frequency in infants or young children |
| MX2017011669A (es) * | 2015-03-13 | 2017-11-06 | Evolve Biosystems Inc | Composiciones que metabolizan o secuestran monomeros libres de azucar y usos de las mismas. |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| SG10201912324XA (en) | 2015-06-15 | 2020-02-27 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| ME03563B (me) | 2015-06-15 | 2020-07-20 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| HUE044617T2 (hu) | 2015-06-15 | 2019-11-28 | 4D Pharma Res Ltd | Baktériumtörzseket tartalmazó készítmények |
| MD3209310T2 (ro) | 2015-11-20 | 2018-06-30 | 4D Pharma Res Ltd | Compoziții care conțin tulpini bacteriene |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| CN114712405A (zh) | 2016-03-04 | 2022-07-08 | 4D制药有限公司 | 包含细菌菌株的组合物 |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| SG11201807809XA (en) * | 2016-03-11 | 2018-10-30 | Evolve Biosystems Inc | A transient commensal microorganism for improving gut health |
| AU2017290900A1 (en) | 2016-07-01 | 2019-01-17 | Infinant Health, Inc | Method for facilitating maturation of the mammalian immune system |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| EP3630137B1 (en) | 2017-05-22 | 2023-05-17 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| MA41708A (fr) | 2017-05-24 | 2020-04-08 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| PL3600364T3 (pl) | 2017-06-14 | 2021-01-11 | 4D Pharma Research Limited | Kompozycje zawierające szczep bakteryjny z rodzaju megasphaera i ich zastosowania |
| SI3638271T1 (sl) | 2017-06-14 | 2021-01-29 | 4D Pharma Research Limited | Sestavki, ki vsebujejo bakterijske seve |
| CN107365705B (zh) * | 2017-07-14 | 2021-01-12 | 江苏微康生物科技有限公司 | 一种油溶性益生菌冻干菌粉的冻干保护剂及其应用 |
| WO2019046646A1 (en) | 2017-08-30 | 2019-03-07 | Whole Biome Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS |
| SG11202002325VA (en) * | 2017-09-13 | 2020-04-29 | Evolve Biosystems Inc | Metabolomic revision of mammalian infants |
| WO2019143871A1 (en) | 2018-01-17 | 2019-07-25 | Evolve Biosystems, Inc. | Activation of conditionally-expressed oligosaccharide pathways during fermentation of probiotic strains |
| WO2019246316A1 (en) * | 2018-06-19 | 2019-12-26 | Evolve Biosystems, Inc. | Novel oligosaccharides for use in prebiotic applications |
| JP2023519115A (ja) * | 2020-03-20 | 2023-05-10 | グリコム・アクティーゼルスカブ | 固形のｈｍｏ製品を提供するための方法及びそれにより得られる固形のｈｍｏ製品 |
| CN116615203A (zh) | 2020-12-11 | 2023-08-18 | 帝斯曼知识产权资产管理有限公司 | 改进的益生元制剂 |
| IT202100024911A1 (it) * | 2021-09-29 | 2023-03-29 | Univ Degli Studi Di Napoli Federico Ii Dipartimento Di Fisica Ettore Pancini | Prebiotico a base di "scotta" delattosata per la prevenzione e gestione della disbiosi intestinale |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101909644A (zh) * | 2007-12-17 | 2010-12-08 | 雀巢产品技术援助有限公司 | 在免疫妥协的个体中机会感染的预防 |
| CN102065872A (zh) * | 2008-05-27 | 2011-05-18 | 雀巢产品技术援助有限公司 | 改善肠微生物群的益生菌 |
| US20130195803A1 (en) * | 2010-07-12 | 2013-08-01 | The Regents Of The University Of California | Bovine milk oligosaccharides |
| CN103582426A (zh) * | 2010-11-23 | 2014-02-12 | 雀巢产品技术援助有限公司 | 寡糖混合物以及包含该混合物的食品，特别是婴儿配方产品 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5716615A (en) | 1992-02-10 | 1998-02-10 | Renata Maria Anna Cavaliere Vesely | Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use |
| RU2180915C1 (ru) | 2001-04-28 | 2002-03-27 | Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского | Консорциум бифидобактерий и лактобацилл, используемый для приготовления бактериальных препаратов, заквасок для кисломолочных продуктов, ферментированных и неферментированных пищевых продуктов, биологически активных добавок, предназначенных для коррекции микрофлоры детей в возрасте до 3-х лет |
| EP2033529B1 (en) * | 2003-10-24 | 2019-12-11 | N.V. Nutricia | Synbiotic composition for infants |
| US20070082087A1 (en) * | 2005-10-06 | 2007-04-12 | Schweitzer Biotech Company Ltd. | Fermented milk products containing bifidobacterium longum and isomalto oligosaccharide and the process for producing the same |
| EP1776877A1 (en) * | 2005-10-21 | 2007-04-25 | N.V. Nutricia | Method for stimulating the intestinal flora |
| CA2690058A1 (en) | 2006-06-09 | 2007-12-13 | 9205-5961 Quebec Inc. | Fermented probiotic beverages and uses thereof |
| EP2069520A4 (en) * | 2006-09-15 | 2010-05-05 | Univ California | GENETIC SEQUENCES OF BIFIDOBACTERIA AND THEIR USE |
| US8197872B2 (en) | 2007-05-17 | 2012-06-12 | The Regents Of The University Of California | Human milk oligosaccharides to promote growth of beneficial gut bacteria |
| WO2008153377A1 (en) * | 2007-06-15 | 2008-12-18 | N.V. Nutricia | Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide |
| UA32462U (uk) | 2008-02-14 | 2008-05-12 | Харьковский Национальный Медицинский Университет | Спосіб оцінки ефективності корекції порушень мікробіоценозу кишечнику у дітей молодшого віку з атопічним дерматитом |
| CA2658440C (en) * | 2008-04-04 | 2016-08-23 | Kraft Foods Global Brands Llc | Dairy composition with probiotics and anti-microbial system |
| EP2143341A1 (en) * | 2008-07-08 | 2010-01-13 | Nestec S.A. | Nutritional Composition Containing Oligosaccharide Mixture |
| MX349706B (es) | 2008-11-11 | 2017-08-09 | Alimentary Health Ltd | Bifidobacterium longum. |
| JP2012510476A (ja) | 2008-12-02 | 2012-05-10 | プロラクタ バイオサイエンス，インコーポレイテッド | ヒト乳透過組成物ならびにその製造および使用方法 |
| US9649380B2 (en) | 2009-01-12 | 2017-05-16 | Pfizer Italia S.R.L. | Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin |
| US8198872B2 (en) | 2009-03-10 | 2012-06-12 | Honeywell International, Inc. | Starter-generator with improved excitation |
| US7888062B1 (en) * | 2010-02-01 | 2011-02-15 | Microbios, Inc. | Process and composition for the manufacture of a microbial-based product |
| KR20120138772A (ko) | 2010-02-19 | 2012-12-26 | 글리콤 에이/에스 | ６’?ｏ?시알릴락토오스 및 중간체의 제조 |
| EP2465509A1 (en) | 2010-11-23 | 2012-06-20 | Nestec S.A. | Oligosaccharide composition for treating acute respiratory tract infections |
| EP2465507A1 (en) * | 2010-11-23 | 2012-06-20 | Nestec S.A. | Oligosaccharide composition for treating skin diseases |
| CN103763940B (zh) * | 2010-12-31 | 2015-10-14 | 雅培制药有限公司 | 促进有益微生物群生长的益生菌和人乳寡糖的合益素组合 |
| AU2012215042B2 (en) * | 2011-02-10 | 2016-01-14 | Société des Produits Nestlé S.A. | Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk |
| US9579353B2 (en) | 2011-06-10 | 2017-02-28 | Prothera, Inc. | Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes |
| ES2728453T3 (es) * | 2012-02-14 | 2019-10-24 | Univ California | Enzimas y métodos para escindir N-glicanos de glicoproteínas |
| US10165788B2 (en) | 2013-06-17 | 2019-01-01 | The Regents Of The University Of California | Methods and compositions for improved digestion of milk oligosaccharides |
| DK3209308T3 (da) | 2014-10-24 | 2022-10-03 | Evolve Biosystems Inc | Aktiverede bifidobakterier og fremgangsmåder til anvendelse deraf |
| EP3229595B1 (en) | 2014-12-12 | 2021-02-03 | The Regents of the University of California | Reduction of milk glycans and their degradation products in the neonate gut |
-
2015
- 2015-10-23 DK DK15853612.8T patent/DK3209308T3/da active
- 2015-10-23 EP EP15853612.8A patent/EP3209308B1/en active Active
- 2015-10-23 CN CN202111546347.2A patent/CN114376234A/zh active Pending
- 2015-10-23 AU AU2015335601A patent/AU2015335601A1/en not_active Abandoned
- 2015-10-23 CA CA2965663A patent/CA2965663C/en active Active
- 2015-10-23 CN CN201580071135.XA patent/CN107249611A/zh active Pending
- 2015-10-23 SG SG11201703298SA patent/SG11201703298SA/en unknown
- 2015-10-23 WO PCT/US2015/057226 patent/WO2016065324A1/en active Application Filing
- 2015-10-23 SG SG10202002593SA patent/SG10202002593SA/en unknown
- 2015-10-23 BR BR112017008284A patent/BR112017008284A8/pt not_active Application Discontinuation
- 2015-10-23 MX MX2017005260A patent/MX2017005260A/es unknown
- 2015-10-23 US US15/521,502 patent/US10716816B2/en active Active
-
2020
- 2020-06-08 US US16/895,641 patent/US20200397837A1/en active Pending
-
2021
- 2021-07-09 AU AU2021204822A patent/AU2021204822A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101909644A (zh) * | 2007-12-17 | 2010-12-08 | 雀巢产品技术援助有限公司 | 在免疫妥协的个体中机会感染的预防 |
| CN102065872A (zh) * | 2008-05-27 | 2011-05-18 | 雀巢产品技术援助有限公司 | 改善肠微生物群的益生菌 |
| US20130195803A1 (en) * | 2010-07-12 | 2013-08-01 | The Regents Of The University Of California | Bovine milk oligosaccharides |
| CN103582426A (zh) * | 2010-11-23 | 2014-02-12 | 雀巢产品技术援助有限公司 | 寡糖混合物以及包含该混合物的食品，特别是婴儿配方产品 |
Non-Patent Citations (2)
| Title |
|---|
| CHICHLOWSKI M ET.AL: "Chichlowski M , De L G , German J B , et al. Bifidobacteria isolated from infants and cultured on human milk oligosaccharides affect intestinal epithelial function.", 《 JOURNAL OF PEDIATRIC GASTROENTEROLOGY & NUTRITION》 * |
| KAVANAUGH DEVON W. ET.AL: "Exposure of Bifidobacterium longum subsp. infantis to Milk Oligosaccharides Increases Adhesion to Epithelial Cells and Induces a Substantial Transcriptional Response.", 《PLOS ONE》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113164532A (zh) * | 2018-05-30 | 2021-07-23 | 进化生物系统股份有限公司 | H5功能性长双歧杆菌婴儿亚种的组合物和使用方法 |
| CN113163836A (zh) * | 2018-06-01 | 2021-07-23 | 进化生物系统股份有限公司 | 促进宿主防御和刺激、扩增和/或重置t细胞库的组合物和方法 |
| CN111826324A (zh) * | 2020-08-05 | 2020-10-27 | 厦门惠盈动物科技有限公司 | 一种鼠李糖乳杆菌菌粉的制备方法 |
| CN114568520A (zh) * | 2020-11-30 | 2022-06-03 | 内蒙古伊利实业集团股份有限公司 | 包含长双歧杆菌婴儿亚种的婴幼儿配方粉及其应用 |
| CN114568516A (zh) * | 2020-11-30 | 2022-06-03 | 内蒙古伊利实业集团股份有限公司 | 包含长双歧杆菌婴儿亚种与母乳低聚糖的组合物及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021204822A1 (en) | 2021-08-05 |
| BR112017008284A8 (pt) | 2023-04-11 |
| AU2015335601A1 (en) | 2017-06-01 |
| CA2965663C (en) | 2023-04-04 |
| EP3209308B1 (en) | 2022-08-03 |
| US20170304375A1 (en) | 2017-10-26 |
| SG10202002593SA (en) | 2020-05-28 |
| MX2017005260A (es) | 2018-01-30 |
| EP3209308A1 (en) | 2017-08-30 |
| BR112017008284A2 (pt) | 2017-12-19 |
| US10716816B2 (en) | 2020-07-21 |
| CA2965663A1 (en) | 2016-04-28 |
| DK3209308T3 (da) | 2022-10-03 |
| CN114376234A (zh) | 2022-04-22 |
| EP3209308A4 (en) | 2018-06-27 |
| WO2016065324A1 (en) | 2016-04-28 |
| SG11201703298SA (en) | 2017-05-30 |
| US20200397837A1 (en) | 2020-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200397837A1 (en) | Activated bifidobacteria and methods of use thereof | |
| US20220313759A1 (en) | Method for facilitating maturation of the mammalian immune system | |
| EP3313423B1 (en) | Compositions comprising bacterial blautia strains for treating visceral hypersensitivity | |
| US20200046782A1 (en) | Transient Commensal Microorganism for Improving Gut Health | |
| ES2527959T3 (es) | Composiciones de permeado de leche humana y métodos para realizarlas y usarlas | |
| CN107019701A (zh) | 使用人乳低聚糖来降低婴儿、幼儿或儿童的坏死性小肠结肠炎的发病率的方法 | |
| RU2704133C2 (ru) | Применение lactobacillus paracasei для усиления восстановления разнообразия кишечной микрофлоры после дисбактериоза | |
| US20220010267A1 (en) | Compostions and method of use for h5 competent bifidobacterium longum subsp. infantis | |
| CN109069549A (zh) | 用于断奶的食物组合物 | |
| CN111480849A (zh) | 母乳化的复合益生菌微胶囊粉及其制备方法和应用 | |
| CN103327828A (zh) | 使用营养组合物抑制病原体的方法 | |
| AU2019237674B2 (en) | Composition for enhancing breast milk component | |
| TW202027767A (zh) | 包含細菌菌株之組合物 | |
| AU2016249380A1 (en) | Human milk compositions and methods of making and using same | |
| JP2022157465A (ja) | 乳幼児用排便促進剤 | |
| Marks | Successful probiotic bifidobacteria | |
| NZ749273A (en) | Method for facilitating maturation of the mammalian immune system | |
| Morelli | The microbiological risk | |
| NZ786165A (en) | A Transient Commensal Microorganism for Improving Gut Health |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171013 |